Michael Thomas Heffernan - Net Worth and Insider Trading

Michael Thomas Heffernan Net Worth

The estimated net worth of Michael Thomas Heffernan is at least $659,774 dollars as of 2023-03-24. Michael Thomas Heffernan is the Director of Collegium Pharmaceutical Inc and owns about 28,023 shares of Collegium Pharmaceutical Inc (COLL) stock worth over $648,452. Michael Thomas Heffernan is also the Director of Trevi Therapeutics Inc and owns about 6,351 shares of Trevi Therapeutics Inc (TRVI) stock worth over $11,322. Details can be seen in Michael Thomas Heffernan's Latest Holdings Summary section.

Transaction Summary of Michael Thomas Heffernan

To

Michael Thomas Heffernan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Michael Thomas Heffernan owns 8 companies in total, including Collegium Pharmaceutical Inc (COLL) , Trevi Therapeutics Inc (TRVI) , and Akebia Therapeutics Inc (AKBA) among others .

Click here to see the complete history of Michael Thomas Heffernan’s form 4 insider trades.

Insider Ownership Summary of Michael Thomas Heffernan

Ticker Comapny Transaction Date Type of Owner
COLL Collegium Pharmaceutical Inc 2022-05-19 director
TRVI Trevi Therapeutics Inc 2019-05-07 director
AKBA Akebia Therapeutics Inc 2018-12-12 director
BHVN Biohaven Pharmaceutical Holding Co Ltd 2020-01-31 director
KERX Keryx Biopharmaceuticals Inc 2018-12-12 director
OCAT Ocata Therapeutics Inc 2016-02-10 director
SYBX Synlogic Inc 2020-12-08 director
BHVN Biohaven Ltd 2022-10-03 director

Michael Thomas Heffernan Latest Holdings Summary

Michael Thomas Heffernan currently owns a total of 2 stocks. Among these stocks, Michael Thomas Heffernan owns 28,023 shares of Collegium Pharmaceutical Inc (COLL) as of December 27, 2022, with a value of $648,452 and a weighting of 98.28%. Michael Thomas Heffernan also owns 6,351 shares of Trevi Therapeutics Inc (TRVI) as of May 9, 2019, with a value of $11,322 and a weighting of 1.72%.

Latest Holdings of Michael Thomas Heffernan

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
COLL Collegium Pharmaceutical Inc 2022-12-27 28,023 23.14 648,452
TRVI Trevi Therapeutics Inc 2019-05-09 6,351 1.78 11,322

Holding Weightings of Michael Thomas Heffernan


Michael Thomas Heffernan Form 4 Trading Tracker

According to the SEC Form 4 filings, Michael Thomas Heffernan has made a total of 20 transactions in Collegium Pharmaceutical Inc (COLL) over the past 5 years, including 0 buys and 20 sells. The most-recent trade in Collegium Pharmaceutical Inc is the sale of 25,041 shares on December 27, 2022, which brought Michael Thomas Heffernan around $590,467.

According to the SEC Form 4 filings, Michael Thomas Heffernan has made a total of 1 transactions in Trevi Therapeutics Inc (TRVI) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Trevi Therapeutics Inc is the acquisition of 2,500 shares on May 9, 2019, which cost Michael Thomas Heffernan around $25,000.

Insider Trading History of Michael Thomas Heffernan

Ticker
Company
Date
Buy/Sell
Insider Trading Shares
Shares Change
Price
Cost
Final Share
Current Price
Price Change Since Insider Trade (%)
Filing Date
COLL
Collegium Pharmaceutical Inc
2022-12-27
Sell
25,041.00
-47.19%
$23.58
$590,467.00
28,023.00
$23.14
-1.87%
2022-12-27
COLL
Collegium Pharmaceutical Inc
2022-12-21
Sell
83,964.00
-74.98%
$23.09
$1,938,730.00
28,023.00
$23.14
0.22%
2022-12-21
COLL
Collegium Pharmaceutical Inc
2022-12-13
Sell
189,607.00
-87.12%
$22.14
$4,197,900.00
28,023.00
$23.14
4.52%
2022-12-14
COLL
Collegium Pharmaceutical Inc
2021-03-15
Sell
50,075.00
-92.52%
$25.30
$1,266,900.00
4,047.00
$23.14
-8.54%
-
COLL
Collegium Pharmaceutical Inc
2020-08-11
Sell
13,071.00
-19.45%
$19.13
$250,048.00
54,122.00
$23.14
20.96%
-
COLL
Collegium Pharmaceutical Inc
2020-05-13
Sell
19,254.00
-19.05%
$21.63
$416,464.00
81,796.00
$23.14
6.98%
-
COLL
Collegium Pharmaceutical Inc
2020-01-21
Sell
295,287.00
-73.58%
$21.93
$6,475,640.00
106,012.00
$23.14
5.52%
-
COLL
Collegium Pharmaceutical Inc
2019-07-15
Sell
25,000.00
-15.92%
$11.26
$281,500.00
132,069.00
$23.14
105.51%
-
COLL
Collegium Pharmaceutical Inc
2019-06-17
Sell
25,000.00
-13.73%
$11.37
$284,250.00
157,069.00
$23.14
103.52%
-
COLL
Collegium Pharmaceutical Inc
2019-05-15
Sell
25,000.00
-12.07%
$12.84
$321,000.00
182,069.00
$23.14
80.22%
-
TRVI
Trevi Therapeutics Inc
2019-05-09
Buy
2,500.00
64.92%
$10.00
$25,000.00
6,351.00
$1.78
-82.17%
-
COLL
Collegium Pharmaceutical Inc
2019-04-15
Sell
25,000.00
-11.00%
$15.09
$377,250.00
202,362.00
$23.14
53.35%
-
COLL
Collegium Pharmaceutical Inc
2019-03-15
Sell
25,000.00
-9.91%
$17.17
$429,250.00
227,362.00
$23.14
34.77%
-
COLL
Collegium Pharmaceutical Inc
2019-02-15
Sell
25,000.00
-9.01%
$14.81
$370,250.00
252,362.00
$23.14
56.25%
-
COLL
Collegium Pharmaceutical Inc
2019-01-15
Sell
25,000.00
-8.04%
$15.56
$389,000.00
286,000.00
$23.14
48.71%
-
COLL
Collegium Pharmaceutical Inc
2018-12-17
Sell
25,000.00
-7.44%
$18.18
$454,500.00
311,000.00
$23.14
27.28%
-
COLL
Collegium Pharmaceutical Inc
2018-11-15
Sell
25,000.00
-6.93%
$16.60
$415,000.00
336,000.00
$23.14
39.40%
-
COLL
Collegium Pharmaceutical Inc
2018-10-15
Sell
25,000.00
-6.48%
$16.53
$413,250.00
361,000.00
$23.14
39.99%
-
COLL
Collegium Pharmaceutical Inc
2018-06-12
Sell
150,000.00
-27.85%
$25.27
$3,790,500.00
388,693.00
$23.14
-8.43%
-
COLL
Collegium Pharmaceutical Inc
2018-05-10
Sell
7,100.00
-1.30%
$26.21
$186,091.00
538,693.00
$23.14
-11.71%
-
Total 24
  • 1
  • 2
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Michael Thomas Heffernan Trading Performance

GuruFocus tracks the stock performance after each of Michael Thomas Heffernan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Michael Thomas Heffernan is -40.12%. GuruFocus also compares Michael Thomas Heffernan's trading performance to market benchmark return within the same time period. The performance of stocks bought by Michael Thomas Heffernan within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Michael Thomas Heffernan's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Michael Thomas Heffernan

Average Relative Return

Outperforming Transactions

Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) 14.69 -40.12 -55.31 -67.28 -49.13 -36.21
Relative Return to S&P 500(%) 14.6 -41.79 -63.06 -69.34 -70.59 -47.81

Michael Thomas Heffernan Ownership Network

Ownership Network List of Michael Thomas Heffernan

No Data

Ownership Network Relation of Michael Thomas Heffernan


Michael Thomas Heffernan Owned Company Details

What does Collegium Pharmaceutical Inc do?

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.

Who are the key executives at Collegium Pharmaceutical Inc?

Michael Thomas Heffernan is the director of Collegium Pharmaceutical Inc. Other key executives at Collegium Pharmaceutical Inc include EVP and Chief Medical Officer Thomas B Smith , EVP & Chief Financial Officer Tupper Colleen , and EVP and Chief Medical Officer Richard Malamut .

Collegium Pharmaceutical Inc (COLL) Insider Trades Summary

Over the past 18 months, Michael Thomas Heffernan made 3 insider transaction in Collegium Pharmaceutical Inc (COLL) with a net sale of 298,612. Other recent insider transactions involving Collegium Pharmaceutical Inc (COLL) include a net sale of 164,703 shares made by Joseph Ciaffoni , a net sale of 60,700 shares made by Shirley R. Kuhlmann , and a net sale of 34,086 shares made by Scott Dreyer .

In summary, during the past 3 months, insiders sold 78,397 shares of Collegium Pharmaceutical Inc (COLL) in total and bought 0 shares, with a net sale of 78,397 shares. During the past 18 months, 562,451 shares of Collegium Pharmaceutical Inc (COLL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 562,451 shares.

Collegium Pharmaceutical Inc (COLL)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

NAS:COLL Insider Transactions

20/Page
Total 0
Insider
Position
Date
Buy/Sell
Shares
Shares Owned
Trade Price($)
Trade Percentage(%)
Cost($1000)
Price change since trade(%)
Share ownership details
Filing Date
20/Page
Total 0

Michael Thomas Heffernan Mailing Address

Above is the net worth, insider trading, and ownership report for Michael Thomas Heffernan. You might contact Michael Thomas Heffernan via mailing address: C/o Cornerstone Therapeutics Inc., 1255 Crescent Green Drive, Suite 250, Cary Nc 27518.